Printer Friendly

Institut Pasteur obtains United States patent.

Institut Pasteur (Paris, France) and Centre National de la Recherche Scientifique (Paris, France) have patented viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre- m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications. (US 7,556,812)
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:May 1, 2009
Words:104
Previous Article:Falcon Genomics awarded patent for innovative cancer test.
Next Article:IACR-Rothamsted obtains United States patent.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters